In a recent interview, Wayne Brisbane, M.D., discussed new research, presented at the American Urological Association (AUA) conference, which revealed a 15 percent higher AUC for an emerging AI software in detecting seminal vesicle invasion (SVI) in comparison to prostate MRI alone.
Magnetic resonance imaging (MRI) and prostate-specific membrane-antigen positron emission tomography (PSMA PET) both have limitations with respect to the detection of seminal vesicle invasion (SVI) in prostate cancer, noted Wayne Brisbane, M.D., in a recent interview.
“One of the issues is (MRI) is not super sensitive so if there's a small amount of seminal vesicle invasion, it might not be picked up, especially if the tumor volume is very small. But it's still important because we would risk adjust those patients and change their treatment paradigms,” noted Dr. Brisbane, an assistant professor of urology at the University of California-Los Angeles (UCLA). “ … With PSMA, there (are) other challenges. While molecular imaging is very easy to interpret, there is less spatial resolution between the prostate and the seminal vesicle so interpreting seminal vesicle invasion with PSMA and MRI can be challenging.”
However, in a recent lecture at the American Urological Association (AUA) Annual Meeting, Dr. Brisbane discussed key findings from a new study examining the use of the MRI-based artificial intelligence (AI) software Unfold AI (Avenda Health) for detecting SVI in patients with prostate cancer.
In an initial cohort of 147 men who underwent radical prostatectomy (with a 17 percent incidence of SVI), the researchers found that the AI software provided 92 percent sensitivity, 89 percent specificity and a 95 percent area under the receiver operating characteristic curve (AUC), 15 percent higher than the AUC for MRI alone (80 percent).1
“(This) AI (software) was initially trained on (prostate) tumor volume but has found really impressive accuracy for predicting cancers coming out of the prostate or into the seminal vesicles,” noted Dr. Brisbane.
(Editor’s note: For related content, see “Study: PSMA PET/CT More Advantageous than MRI for Locoregional Staging of Prostate Cancer,” “Researchers Unveil PI-QUAL v2 for Prostate MRI Quality Assessments” and “Study Shows PET MRI Offers Better Detection of Localized Prostate Cancer than mpMRI.”)
For more insights from Dr. Brisbane, watch the video below.
Reference
1. Brisbane W, Priester A, Mota SM, et al. Prediction of seminal vesicle invasion using artificial intelligence prostate cancer risk mapping. J Urology. 2025 May 1. https://doi.org/10.1097/01.JU.0001109868.09667.98.20 . Presented at the American Urological Association (AUA) Annual Meeting April 26-29, 2025, Las Vegas.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.